TokenPost·
EMA Panel Recommends Expanded Use of Merck’s Enflonsia in Europe
The Committee for Medicinal Products for Human Use backed a broader indication for the RSV prevention treatment, whose active ingredient is clesrovimab.
More news
- TokenPostGINSMS Posts C$817,005 in Continuing-Operations Revenue Through Sept. 30, 2026
- TokenPostMadison Pacific Properties Reports $0.27 in Nine-Month GAAP EPS
- TokenPostAppili Therapeutics Posts C$3.5 Million First-Half Net Loss
- Crypto BriefingTelegram founder Pavel Durov challenges hackers after security fix
- TokenPostAnthropic CEO Says Too Little Compute Risks Customers, Excess Threatens Solvency
- TokenPostEnergous Expects Q4 Growth Acceleration, Mid-30% Hardware Margins in H1 2027